The issue of pregnant women with BCR/ABL negative myeloproliferative neoplasms
Authors:
J. Kissová 1; M. Penka 1; P. Ovesná 2; A. Buliková 1; R. Gerychová 3
Authors‘ workplace:
Oddělení klinické hematologie Fakultní nemocnice Brno
1; Institut biostatistiky a analýz Masarykovy univerzity Brno
2; Gynekologicko-porodnická klinika Fakultní nemocnice Brno a Lékařská fakulta Masarykovy univerzity Brno
3
Published in:
Transfuze Hematol. dnes,19, 2013, No. 4, p. 197-208.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
The clinical course of BCR/ABL negative myeloproliferative neoplasms is often complicated by thrombotic and to a lesser extent bleeding complications. Although these diseases are generally considered to be diseases of older age, about 20% of patients with essential thrombocythemia are under 40 years. Increasing age of pregnant women and improvement of diagnostics has led to an increased incidence of pregnancy in the course of these diseases. The incidence of pregnancy associated complications is higher compared to other pregnancies, and reproductive losses in these women are 2–3 times more frequent. The most common complications of such pregnancies are spontaneous abortion in the first trimester (25–40%) and late foetal loss (8–21%). Intrauterine foetal growth retardation, stillbirth and placental abruption are less common. These complications arise regardless of the number of platelets and occur more frequently in patients with complications during previous pregnancies and with the presence of JAK2 V617F mutation. The limited number of published data makes it difficult to get a clear view of the overall risk of these events. Therapeutic options range from the administration of aspirin, low molecular weight heparin to targeted cytoreductive depending on the given patient’s risk factors.
In this work, we evaluated retrospective data from a group of 7 women with a total number of 14 pregnancies and the diagnosis of BCR/ABL negative myeloproliferative disorders. In concurrence with published data, a higher incidence of pregnancy complications was found, especially in patients with positive JAK2 V617F mutation. The low number of pregnancies in single centres does not allow for any clear conclusions regarding both the risk factors for pregnancy complications and therapeutic recommendations. The limited data published on this issue is a call for cooperation not only at national, but also international level.
Key words:
myeloproliferative neoplasm, pregnancy, thrombocythemia, polycythemia, myelofibrosis
Sources
1. Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 2005; 129: 293-306.
2. Lavi N, Brenner B, Avivi I. Management of pregnant women with myeloproliferative neoplasms. Thromb Res 2013; 131(Suppl 1):S11-3.
3. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Throm Hemost 2003; 29: 125-30.
4. Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004; 114: 409-14.
5. Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Hemost 2006; 32: 422-9.
6. Prine LW, MacNaughton H. Office management of early pregnancy loss. Am Famil Physician 2011; 84: 75-82.
7. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ 1997; 315: 32-4.
8. Wang X, Chen C, Wang L, Chen D, Guang W, French J. Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. Fertil Steril 2003; 79: 577-84.
9. Middeldorp S. How I treat pregnancy-related venous thromboembolism. Blood 2011; 118: 5394-400.
10. Greer IA. Thrombosis in pregnancy: updates in diagnosis and management. Hematology Am Soc Hematol Educ Program 2012; 2012: 203-7.
11. Harrison CN, Robinson SE. Myeloproliferative disorders in pregnancy. Hematol Oncol Clin North Am 2011; 25: 261-75.
12. Bangerter M, Güthner C, Beneke H, Hildebrand A, Grünewald M, Griesshammer M. Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies. Eur J Hematol 2000; 65: 165-9.
13. Pagliaro P, Arrigoni L, Muggiasca ML, Poggio M, Russo U, Rossi E. Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. Am J Hematol 1996; 53: 6-10.
14. Niittyvuopio R, Juvonen E, Kaaja R, et al. Pregnancy in essential thrombocythaemia: experience with 40 pregnancies. Eur J Haematol 2004; 73: 431-6.
15. Gangat N, Wolanskyj AP, Schwager S, Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol 2009; 82: 350-3.
16. Melillo L, Tieghi A, Candoni A, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from Italian registry. Am J Hematol 2009; 84: 636-640.
17. Passamonti F, Rumi E, Randi ML, Morra E, Cazzola M. Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. J Thromb Haemost 2010; 8: 411-3.
18. Palandri F, Polverelli N, Ottaviani E, Castagnetti F, Baccarani M, Vianelli N. Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. Haematologica 2010; 95: 1038-40.
19. Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2012; 2012: 571-81.
20. Penka M, Schwarz J, Pavlík T, et al. Jak léčíme nemocné s esenciální trombocytémií a dalšími myeloproliferacemi provázenými trombocytémií a co může být prediktivní známkou rizika trombózy u těchto nemocných- zpráva z registru pacientů léčených Thromboreductinem. Vnitř Lék 2008; 54:775-82.
21. Schwarz J, Penka M, Campr V, et al. Diagnostika a léčba BCR/ABL-negativních myeloproliferativních onemocnění – principy a východiska doporučení CZEMP. Vnitř Lék 2011; 57:189-213.
22. Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (V617F) mutation. Blood 2007; 110: 485-489.
23. Dahabreh IJ, Jones AV, Voulgarelis M, et al. No evidence for increased prevalence of JAK2 V617F in women with a history of recurrent miscarriage. Br J Haematol 2009; 144: 802-3.
24. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. European LeukemiaNet. J Clin Oncol 2011; 29: 761-70.
25. Harrison CN, Bareford D, Butt N, et al. British Committee for Standards in Haematology. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010; 149: 352-75.
26. Sejeny SA, Eastham RD, Baker SR. Platelet counts during normal pregnancy. J Clin Pathol 1975; 28: 812-3.
27. Gernsheimer TB. Thrombocytopenia in pregnancy: is this immune thrombocytopenia or...? Hematology Am Soc Hematol Educ Program 2012; 2012: 198-202.
28. Cairns JW, Mahon A, Waters DA, Chanarin I. Platelet levels in pregnancy. J Clin Pathol 1977; 30: 392.
29. Chow EY, Haley LP, Vickars LM. Essential thrombocythemia in pregnancy: platelet count and pregnancy outcome. Am J Hematol 1992; 41: 249-51.
30. Spivak JL. The optimal management of polycythaemia vera. Br J Haematol 2002; 116: 243-54.
31. McMullin MF, Bareford D, Craig J, et al. The optimal management of polycythaemia vera. Br J Haematol 2003; 120: 543-4.
32. Sobas MA, Pérez Encinas MM, Rabuñal Martinez MJ, Quinteiro García C, Bello López JL. Anagrelide treatment in early pregnancy in a patient with JAK2V617F-positive essential thrombocythemia: case report and literature review. Acta Haematol 2009; 122: 221-2.
33. Wright CA, Tefferri A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 2001; 66: 152-9.
34. Doubek M, Brychtova Y, Doubek R, Janku P, Mayer J. Anagrelide therapy in pregnancy: report of a case of essential thrombocythemia. Ann Hematol 2004; 83: 726-7.
35. Hasselbalch HC. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011; 4: 637-55.
36. Kumar AR, Hale TW, Mock RE. Transfer of interferon alfa into human breast milk. J Hum Lact 2000; 16: 226-8.
37. Koh LP, Devendra K, Tien SL. Four pregnancies in two patients with essential thrombocythaemia-a case report. Ann Acad Med Singapore 2002; 31: 353-6.
38. Beard J, Hillmen P, Anderson CC, Lewis SM, Pearson TC. Primary thrombocythaemia in pregnancy. Br J Haematol 1991; 77: 371-4.
39. Tefferi A, Passamonti F. Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. Am J Hematol 2009; 84: 629-30.
40. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994; 343: 619-29.
41. Nørgård B, Fonager K, Pedersen L, Jacobsen BA, Sørensen HT. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut 2003; 52: 243-7.
42. Demmers KJ, Derecka K, Flint A. Trophoblast interferon and pregnancy. Reproduction 2001; 121: 41-9.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2013 Issue 4
Most read in this issue
- Phlebotomy and therapeutic apheresis in the treatment of polyglobulia
- Antithrombin
- Stability of coagulation factors in thawed plasma
- Malignant tumours in adult patients after successful treatment of acute myeloid leukemia: long-term experience at the Department of Hemato-Oncology in Olomouc